Bartholomew Savino, MD
Internal Medicine · Staten Island, NYNPI 1306911417
Payments from drug & device makers
Across 215 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$800
- Bayer$800
- Lilly USA, LLC$451
- AstraZeneca$351
- Amgen$184
- GSK$155
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,94299%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $800 |
| Bayer | 47 | $800 |
| Lilly USA, LLC | 22 | $451 |
| AstraZeneca | 21 | $351 |
| Amgen | 9 | $184 |
| GSK | 9 | $155 |
| Pfizer | 9 | $139 |
| Novo Nordisk | 6 | $123 |
| Merck | 6 | $87 |
| Johnson & Johnson | 5 | $83 |
| Boehringer Ingelheim | 4 | $81 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Exact Sciences | 3 | $70 |
| Astellas Pharma US Inc | 3 | $66 |
| Inspire Medical Systems, Inc. | 1 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $57 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Novartis | 2 | $30 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Neurelis, Inc. | 1 | $21 |
| Otter Pharmaceuticals, LLC | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Ceribell, Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
How this compares
$3,981 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $122,721 |
| EliquisApixaban | 92 | $75,659 |
| JanumetSitagliptin Phos/Metformin Hcl | 68 | $65,518 |
| MounjaroTirzepatide | 31 | $34,252 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $29,253 |
| JardianceEmpagliflozin | 19 | $25,977 |
| JanuviaSitagliptin Phosphate | 26 | $24,414 |
| FarxigaDapagliflozin Propanediol | 18 | $19,040 |
| EntrestoSacubitril/Valsartan | 20 | $18,643 |
| XareltoRivaroxaban | 24 | $18,433 |
| TradjentaLinagliptin | 19 | $15,213 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $14,861 |
| LinzessLinaclotide | 28 | $14,801 |
| BelsomraSuvorexant | 12 | $10,725 |
| MyrbetriqMirabegron | 20 | $9,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $123 | $122,72196 claims |
| MerckJanumet, Januvia, Belsomra | $87 | $100,657106 claims |
| PfizerEliquis | $139 | $75,65992 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $155 | $49,66598 claims |
| Boehringer IngelheimJardiance, Tradjenta | $81 | $41,18938 claims |
| Lilly USA, LLCMounjaro | $451 | $34,25231 claims |
| AstraZenecaFarxiga, Symbicort | $351 | $26,80144 claims |
| NovartisEntresto | $30 | $18,64320 claims |
| Johnson & JohnsonXarelto | $83 | $18,43324 claims |
| AbbVieLinzess, Synthroid | $800 | $16,72065 claims |
| Astellas Pharma US IncMyrbetriq | $66 | $9,57920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Staten Island
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.